Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KIDS
stocks logo

KIDS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
59.28M
+12.55%
-0.319
-53.83%
58.73M
+12.06%
-0.443
-3.73%
68.64M
+12.38%
-0.330
+10%
Estimates Revision
The market is revising Downward the revenue expectations for OrthoPediatrics Corp. (KIDS) for FY2025, with the revenue forecasts being adjusted by -2.28% over the past three months. During the same period, the stock price has changed by -13.10%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.28%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+19.81%
In Past 3 Month
Stock Price
Go Down
down Image
-13.10%
In Past 3 Month
Wall Street analysts forecast KIDS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KIDS is 24.00 USD with a low forecast of 18.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast KIDS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KIDS is 24.00 USD with a low forecast of 18.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.170
sliders
Low
18.00
Averages
24.00
High
34.00
Current: 18.170
sliders
Low
18.00
Averages
24.00
High
34.00
Needham
Needham
Buy
downgrade
$42 -> $26
2025-10-29
Reason
Needham
Needham
Price Target
$42 -> $26
2025-10-29
downgrade
Buy
Reason
Needham lowered the firm's price target on OrthoPediatrics to $26 from $42 and keeps a Buy rating on the shares. The company's Q3 revenue was just above its pre-announcement and adjusted EBITDA missed consensus, the analyst tells investors in a research note. OrthoPediatrics previously indicated that it now expects revenue growth of over 12% over the next few years, and while this is conservative and leaves room for potential upside, the firm is lowering its price target given its lower revenue growth forecasts, Needham added.
Citizens JMP
David Turkaly
Outperform
downgrade
$50 -> $35
2025-08-08
Reason
Citizens JMP
David Turkaly
Price Target
$50 -> $35
2025-08-08
downgrade
Outperform
Reason
Citizens JMP analyst David Turkaly lowered the firm's price target on OrthoPediatrics to $35 from $50 and keeps an Outperform rating on the shares. OrthoPediatrics reported a quarterly record on its top line, though revenues and adjusted EBITDA were shy of consensus, but the company continues to take share in all of its key market segments, and full-year guidance was largely reiterated, the analyst tells investors in a research note. The firm believes the fundamentals around the business remain solid.
BTIG
Buy
maintain
$40 -> $39
2025-08-06
Reason
BTIG
Price Target
$40 -> $39
2025-08-06
maintain
Buy
Reason
BTIG lowered the firm's price target on OrthoPediatrics to $39 from $40 and keeps a Buy rating on the shares after its Q2 results. Trauma & Deformity - T&D - performance was soft in the quarter, but this was offset by an 11.6% beat within Scoliosis, while gross margin and operating margin missed the Street by 170bps and 720bps, the analyst tells investors in a research note.
Truist
Hold
downgrade
$26 -> $22
2025-08-06
Reason
Truist
Price Target
$26 -> $22
2025-08-06
downgrade
Hold
Reason
Truist lowered the firm's price target on OrthoPediatrics to $22 from $26 and keeps a Hold rating on the shares after its Q2 results. The firm continues to like the momentum drivers and ramping profit story for this uniquely positioned asset, but it will take more steady/larger magnitude of beats/raises to support multiple expansion, the analyst tells investors in a research note.
BTIG
Buy
maintain
$38 -> $40
2025-07-14
Reason
BTIG
Price Target
$38 -> $40
2025-07-14
maintain
Buy
Reason
BTIG raised the firm's price target on OrthoPediatrics to $40 from $38 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
Piper Sandler
Matt O'Brien
Overweight
downgrade
$40 -> $30
2025-05-08
Reason
Piper Sandler
Matt O'Brien
Price Target
$40 -> $30
2025-05-08
downgrade
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on OrthoPediatrics to $30 from $40 and keeps an Overweight rating on the shares. The firm notes OrthoPediatrics reported Q1 results which beat soundly on the top-line and gross margins too. Adjusted EBITDA was a little light, but Piper just did not model this metric appropriately and the progress here is completely intact. The firm believes investors need to buy the stock at these levels as management is building a valuable pediatric technology provider that is underappreciated by the market.
See All Ratings

Valuation Metrics

The current forward P/E ratio for OrthoPediatrics Corp (KIDS.O) is -13.72, compared to its 5-year average forward P/E of -43.45. For a more detailed relative valuation and DCF analysis to assess OrthoPediatrics Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-43.45
Current PE
-13.72
Overvalued PE
-23.61
Undervalued PE
-63.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
273.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
703.49
Undervalued EV/EBITDA
-156.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.97
Current PS
0.00
Overvalued PS
9.22
Undervalued PS
2.73
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 114.29% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KIDS News & Events

Events Timeline

(ET)
2025-11-13
07:19:05
OrthoPediatrics Enhances Bracing Line with Launch of Two New Products
select
2025-10-28 (ET)
2025-10-28
16:23:52
OrthoPediatrics Announces FDA Approval for 3P Pediatric Plating Platform System
select
2025-10-28
16:20:57
OrthoPediatrics projects FY25 revenue between $233.5M and $234.5M, below consensus estimate of $235.47M.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-13Newsfilter
OrthoPediatrics Corp. Enhances Specialty Bracing Line with Launch of Two New Products

  • New Product Launches: OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing portfolio with the introduction of the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, aimed at treating Developmental Dysplasia of the Hip (DDH) in children aged three years and younger.

  • Collaboration with Experts: The new products were developed in collaboration with leading pediatric hip specialists, enhancing treatment options for patients and their families.

  • Commitment to Pediatric Care: Joe Hauser, President of the Specialty Bracing division, emphasized the company's focus on organic product development and its commitment to improving pediatric orthopedic care through innovative solutions.

  • Comprehensive Product Offering: Founded in 2006, OrthoPediatrics markets over 85 products across various pediatric orthopedic categories, including trauma, deformity, scoliosis, and sports medicine, serving both the U.S. and international markets.

[object Object]
Preview
4.0
11-10Yahoo Finance
What Factors Might Influence the OrthoPediatrics Narrative Following Analyst Updates?

  • Analyst Price Target Changes: OrthoPediatrics' consensus analyst price target has been lowered from $26.29 to $24.14, reflecting a cautious outlook amid mixed research commentary and short-term challenges.

  • Bullish Analyst Sentiment: Despite the lowered price targets, several firms maintain positive ratings, emphasizing confidence in the company's core business and long-term prospects, particularly in high-margin product lines.

  • Bearish Analyst Concerns: Some analysts express caution, citing near-term headwinds and lower guidance, with notable reductions in price targets and concerns over revenue visibility impacting future growth expectations.

  • Company Developments: OrthoPediatrics announced an intangible asset impairment of $2.27 million, received FDA approval for a new system, and revised its 2025 revenue guidance downward, while also reporting improved net profit margins.

[object Object]
Preview
4.0
10-29Benzinga
Understanding OrthoPediatrics: Key Takeaways from 9 Analyst Evaluations

  • Analyst Ratings Overview: OrthoPediatrics has received mixed ratings from analysts, with 6 bullish, 3 somewhat bullish, and no bearish ratings in the last 30 days, reflecting a shift in sentiment compared to previous months.

  • Price Target Adjustments: Analysts have lowered their 12-month price targets for OrthoPediatrics, with an average target now at $27.44, down from $36.44, indicating a decrease in expected stock performance.

  • Financial Performance Metrics: The company has shown a revenue growth rate of approximately 15.68% and maintains a net margin of -11.64%, outperforming industry standards in terms of financial performance.

  • Debt Management and Ratios: OrthoPediatrics has a debt-to-equity ratio of 0.27, which is below industry norms, suggesting a solid financial structure and effective management of shareholder equity.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is OrthoPediatrics Corp (KIDS) stock price today?

The current price of KIDS is 18.17 USD — it has increased 1.34 % in the last trading day.

arrow icon

What is OrthoPediatrics Corp (KIDS)'s business?

OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.

arrow icon

What is the price predicton of KIDS Stock?

Wall Street analysts forecast KIDS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KIDS is 24.00 USD with a low forecast of 18.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is OrthoPediatrics Corp (KIDS)'s revenue for the last quarter?

OrthoPediatrics Corp revenue for the last quarter amounts to 61.25M USD, increased 12.23 % YoY.

arrow icon

What is OrthoPediatrics Corp (KIDS)'s earnings per share (EPS) for the last quarter?

OrthoPediatrics Corp. EPS for the last quarter amounts to -0.50 USD, increased 47.06 % YoY.

arrow icon

What changes have occurred in the market's expectations for OrthoPediatrics Corp (KIDS)'s fundamentals?

The market is revising Downward the revenue expectations for OrthoPediatrics Corp. (KIDS) for FY2025, with the revenue forecasts being adjusted by -2.28% over the past three months. During the same period, the stock price has changed by -13.10%.
arrow icon

How many employees does OrthoPediatrics Corp (KIDS). have?

OrthoPediatrics Corp (KIDS) has 562 emplpoyees as of December 05 2025.

arrow icon

What is OrthoPediatrics Corp (KIDS) market cap?

Today KIDS has the market capitalization of 455.66M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free